With Celgene Acquisition Closed, Bristol Faces Major Milestones
Executive Summary
Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue.
You may also be interested in...
Lenalidomide Launch Kicks Off A Year Of Revlimid Competition
Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.
BMS Projects 2022 Growth Even With $3bn Hit From Revlimid, Abraxane Generics
Bristol executives reiterated the company’s aggressive revenue growth expectations while outlining the impact Revlimid generics will have in Europe, Japan and – to a limited extent – in the US.
BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near
New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.